drugset / Trial / NCT01504776
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
Timeline
- Start
- 2011-04
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 15 mg | Oral |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |
| Subject | Panobinostat | Small molecule | 25 mg | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |